As we enter the second half of the year, pharma companies are still frantically engaged in the search for a COVID-19 vaccine. There are many companies in the mix, but it is not a level playing field, as big players are pitted against smaller names. At the onset of the pandemic, Novavax (NVAX) stood squarely in the latter camp. Facing pharma giants such as Pfizer, AstraZeneca and J&J, the small-cap biotech was at a disadvantage from the start. However, the vaccine specialist has become a force to be reckoned with. The incredible share gains (almost 1,855% year-to-date) which have pushed …read more
Source:: Yahoo Finance
